BioArctic AB (publ) (STO:BIOA.B)
276.20
+3.80 (1.40%)
Sep 11, 2025, 5:29 PM CET
BioArctic AB Employees
BioArctic AB had 107 employees as of December 31, 2024. The number of employees increased by 19 or 21.59% compared to the previous year.
Employees
107
Change (1Y)
19
Growth (1Y)
21.59%
Revenue / Employee
15.63M SEK
Profits / Employee
8.97M SEK
Market Cap
24.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 107 | 19 | 21.59% |
Dec 31, 2023 | 88 | 27 | 44.26% |
Dec 31, 2022 | 61 | 12 | 24.49% |
Dec 31, 2021 | 49 | 4 | 8.89% |
Dec 31, 2020 | 45 | 3 | 7.14% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Swedish Orphan Biovitrum AB | 1,806 |
Sectra AB | 1,296 |
Getinge AB | 11,791 |
Camurus AB | 256 |
Medicover AB | 47,256 |
Asker Healthcare Group AB | 4,030 |
AddLife AB | 2,181 |
Bonesupport Holding AB | 139 |
BioArctic AB News
- 3 days ago - BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 - PRNewsWire
- 9 days ago - BioArctic's founders intend to divest minor part of their shareholding - PRNewsWire
- 10 days ago - Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status - PRNewsWire
- 14 days ago - US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease - PRNewsWire
- 15 days ago - BioArctic: Interim Report for the period April - June 2025 - PRNewsWire
- 17 days ago - BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - PRNewsWire
- 18 days ago - Leqembi® (lecanemab) launched in the EU today - PRNewsWire
- 22 days ago - Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET - PRNewsWire